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Introduction: Despite being a leading infectious cause of childhood disability globally, testing for cytomegalovirus 
(CMV) infections in pregnancy is generally not done in Sub‑Sahara Africa (SSA), where breastfeeding practice is almost 
universal. Whilst CMV and human immunodeficiency virus (HIV) are both endemic in SSA, the relationship between 
antenatal plasma CMV‑DNA, HIV‑1‑RNA levels and HIV‑1‑mother to child transmission (MTCT) including pregnancy 
outcomes remains poorly described.
Methods: Pregnant women at least 20 weeks’ gestational age at enrolment were recruited from relatively poor 
high‑density suburbs in Harare, Zimbabwe. Mother‑infant dyads were followed up until 6 months postpartum. In a 
case–control study design, we tested antenatal plasma CMV‑DNA levels in all 11 HIV‑1 transmitting mothers, as well as 
randomly selected HIV‑infected but non‑transmitting mothers and HIV‑uninfected controls.
CMV‑DNA was detected and quantified using polymerase chain reaction (PCR) technique. Antenatal plasma HIV‑1‑
RNA load was quantified by reverse transcriptase PCR. Infants’ HIV‑1 infection was detected using qualitative proviral 
DNA‑PCR. Predictive value of antenatal plasma CMV‑DNAemia (CMV‑DNA of > 50 copies/mL) for HIV‑1‑MTCT was 
analyzed in univariate and multivariate regression analyses. Associations of CMV‑DNAemia with HIV‑1‑RNA levels and 
pregnancy outcomes were also explored.
Results: CMV‑DNAemia data were available for 11 HIV‑1 transmitting mothers, 120 HIV‑infected but non‑transmitting 
controls and 46 HIV‑uninfected mothers. In a multivariate logistic regression model, we found a significant association 
between CMV‑DNAemia of > 50 copies/mL and HIV‑1 vertical transmission (p = 0.035). There was no difference in fre‑
quencies of detectable CMV‑DNAemia between HIV‑infected and ‑uninfected pregnant women (p = 0.841). However, 
CMV‑DNA levels were higher in immunosuppressed HIV‑infected pregnant women, CD4 < 200 cells/µL (p = 0.018). 
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Key point
Antenatal plasma CMV-DNA of > 50 copies/mL may be 
an independent risk factor for HIV-1 vertical transmis-
sion in resource limited settings.
Introduction
Cytomegalovirus (CMV) is a common infection in 
humans. The typical disease course is subclinical in at 
least 90% of primary or non-primary infections in immu-
nocompetent hosts. However, following infection, CMV 
persists indefinitely in human hosts [1]. In developing 
countries, there is near-universal CMV sero-prevalence 
from infancy [2]. On the other hand in developed coun-
tries CMV sero-prevalence increases with age, with 
infection rates of 36%, 50% and 91% among 6–11, 30- and 
80-year-olds, respectively [3].
Even in immunocompetent hosts the significance of 
CMV infection is increasingly implicated in comorbidi-
ties, since CMV seropositive individuals have systemic 
immune-dysregulation associated with increased risks 
of cardiovascular diseases and pneumonia [4–6]. CMV 
infection is even more important in immunocompro-
mised hosts such as individuals with human immuno-
deficiency virus (HIV) infection and graft recipients, in 
whom CMV can cause severe disease such as pneumo-
nitis [7] and meningitis [8]. It remains an important co-
infection in HIV-infected adults even  among those on 
successful combination antiretroviral therapy (cART) 
with good viral control, and has been associated with 
increased morbidity and mortality, including the devel-
opment of non-AIDS-defining illnesses (9;10). CMV 
reactivation or disease may be under-reported in high 
CMV/HIV sero-prevalence settings where access to 
CMV screening and treatment are limited due to pov-
erty, compounded by the unavailability of such services 
in public health care facilities.
CMV reactivation often occurs during pregnancy, 
more frequently in HIV-infected women including 
those on cART [1, 2]. In our clinical setting,  infection is 
nearly universal with 99.6% of pregnant women show-
ing chronic (non-primary) CMV infection [11]. How-
ever, preconception CMV immunity provides limited 
protection as intrauterine transmission can occur in 
women who are  sero-immune prior to pregnancy [12]. 
CMV has been shown to replicate at the uterine-placen-
tal interface, potentially impairing vascular remodelling 
thereby occluding blood flow causing local hypoxia and 
other adverse foetal outcomes [13].
CMV is the leading infectious cause of congenital 
abnormalities and permanent disabilities. CMV-MTCT 
rate is 2% in developed countries with up to 15% of the 
infected new-borns being symptomatic, presenting with 
microcephaly and intrauterine growth restriction [14]. 
Furthermore, up to 15% of the initially asymptomatic 
infants progress to develop long term morbidities such 
as non-genetic sensorineural hearing loss, severe motor 
developmental and visual impairment as well as vary-
ing degrees of adverse neurodevelopmental outcomes, 
including cerebral palsy, seizures and intellectual dis-
ability [15]. CMV also remains a risk factor for child-
hood acute lymphocytic leukaemia [16]. Despite all 
these health problems and/or disabilities, there is poor 
awareness of congenital CMV (cCMV) among women 
of reproductive age in both developed and developing 
countries [17–19]. Furthermore, the exact pathogenesis 
remains largely unknown but could be due to a complex 
interplay between, placental, foetal, maternal and viral 
factors [20].
The role of maternal CMV replication on adverse 
pregnancy outcomes and infant health remains poorly 
understood in SSA with near-universal adult CMV infec-
tion and high HIV-1 sero-prevalence. Furthermore, 
in the same setting breastfeeding is the norm regard-
less of maternal HIV status. It is plausible that maternal 
CMV reinfection and/or reactivation may be contribut-
ing to the relatively higher HIV-1 vertical transmission 
rates and other adverse pregnancy outcomes common 
in this setting, but this has not been adequately investi-
gated. In this pilot study we investigated the association 
between antenatal plasma CMV-DNA levels and HIV-1 
vertical transmission events, plasma HIV-1-RNA load 
and pregnancy outcomes in a subgroup of pregnant 
women ≥ 20  weeks gestational age participating in the 
University of Zimbabwe Birth Cohort Study (UZBCS).
Non‑significant associations of more preterm births (< 37 weeks, p = 0.063), and generally lower birth weights 
(< 2500 g, p = 0.450) were observed in infants born of HIV‑infected mothers with CMV‑DNAemia. Furthermore, in a 
multivariate analysis of HIV‑infected but non‑transmitting mothers, CMV‑DNAemia of > 50 copies/mL correlated sig‑
nificantly with antenatal plasma HIV‑1‑RNA load (p = 0.002).
Conclusion: Antenatal plasma CMV‑DNA of > 50 copies/mL may be an independent risk factor for HIV‑1‑MTCT and 
higher plasma HIV‑1‑RNA load, raising the possibility that controlling antenatal CMV‑DNAemia might improve infant 
health outcomes. Further studies with larger sample sizes are warranted to confirm our findings.
Keywords: Antenatal CMV‑DNAemia, HIV‑1‑RNA load, Birth outcomes, Infant health, HIV‑1 vertical transmission
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Methods
Design of University of Zimbabwe birth cohort study 
(UZBCS)
The UZBCS aims to investigate the role of maternal 
comorbidities, including co-infections with persis-
tent viruses such as HIV, CMV, hepatitis B virus, and 
other infectious or non-communicable diseases includ-
ing maternal nutritional status on pregnancy outcomes, 
infant mortality, development, immunity and health. 
By design, approximately 50% of the expecting women 
the UZBCS are HIV-infected. Briefly, at enrolment all 
women answered a structured questionnaire aiming at a 
comprehensive clinical, socio-demographic, environmen-
tal and household characterization of the research partic-
ipants. Further, socio-economic information comprising 
employment status, family monthly income, money set 
aside for food were recorded including general household 
food security. Date for cART commencement and com-
pliance were recorded in HIV-infected women. Accord-
ing to Zimbabwean national guidelines, all HIV-infected 
women should be on lifelong cART (Option B +), but in 
practice pregnant women often do not receive a timely 
HIV diagnosis. The current standard of care for all Zim-
babwean HIV-infected pregnant women to prevent 
HIV MTCT consists of (non)–nucleoside reverse tran-
scriptase inhibitors; TENOLAM-E (Tenofovir, Lamivu-
dine and Efavirenz. Mothers breastfeed as long as they 
wish to. However, exclusive breastfeeding is encouraged 
during the first six months of life.
All HIV exposed infants are commenced on Cotri-
moxazole prophylaxis until they stop breastfeeding or 
they test HIV-PCR positive, whichever occurs first. Upon 
detection of HIV-1 infection, infants are immediately 
commenced on cART, usually comprising the protease 
inhibitors Lopinavir/ritonavir and nucleoside reverse 
transcriptase inhibitors, Zidovudine and Lamivudine.
The UZBCS recruited 600 HIV-infected and 600 HIV-
uninfected pregnant women at least 20  weeks of gesta-
tion from February 2016 until June 2019. Mother-infant 
dyads will be followed for 2 years, with an expected study 
completion date in June 2021.
Selection of participants at enrolment into UZBCS
Potential participants for the cohort were identified dur-
ing routine antenatal care visits at any one of the four 
out of a total of twelve City of Harare Polyclinics, situ-
ated in the South-western high-density areas of Harare 
namely, Kuwadzana, Rujeko, Budiriro and Glenview. Res-
idents of these communities are of relatively poor socio-
economic status. Follow-up visits of the mother-infant 
dyads were performed at delivery, within 10 days of life 
and 6, 10, 14 and 24 weeks postpartum. Date and mode 
of delivery, birth weight and length, feeding practices and 
information on the general health and development of 
infants were also collected.
Selection of participants for CMV analysis from UZBCS 
participants
Data and bio-samples were available from the first 527 
mothers recruited consecutively from February 2016 
and August 2017, of which 280 were HIV-infected. Due 
to financial   limitations, CMV-DNAemia measurements 
were only possible in a subgroup of pregnant women. We 
first selected all mothers who  transmitted HIV to their 
infants by 6  months of age (n = 11) as MTCT cases. A 
total of 120 HIV-infected but non-transmitting mothers 
were randomly selected as controls by a computer Pseudo 
Random Number generated algorithm. Three of these 
women gave birth to live twins. Depending on respective 
analyses’ outcomes we referred to this group as 120 HIV-
infected but non-transmitting mothers or 123 infant-
mother dyads. An additional 46 HIV-uninfected controls 
and their infants were also randomly selected using the 
same procedure.
Blood collection and analysis
Ten millilitres of maternal venous blood was collected 
at enrolment. Maternal HIV diagnosis was done using 
qualitative rapid immunochromatographic assays, SD 
Bioline HIV-1/2 3.0 (Standard Diagnostics Inc., Kyonggi-
do, South Korea) and Abbott’s Determine® HIV-1/2. 
Western Blot was the tie breaker for any indeterminate 
test results.
Full blood counts were determined from whole ethyl-
enediaminetetraacetic acid (EDTA) blood samples using 
a Mindray© Haematology 3-part differential, 16 param-
eters BC3600 Analyser (Shenzhen, China). For diagnosis 
of anaemia in pregnancy, the World Health Organisation 
(WHO) definition was used (haemoglobin < 11.0  g/dL) 
[21].
Absolute  CD4+ T-lymphocyte counts in EDTA blood 
samples were enumerated within a maximum of 6 h after 
sample acquisition for all HIV-infected mothers using 
a Partec Cyflow counter (Cyflow, Partec, Munster, 
Germany).
Maternal CMV/HIV detection and quantification
For analysis of HIV-RNA and CMV-DNA  loads, blood 
was centrifuged for 5  min at 3000  rpm and the plasma 
was aliquoted in appropriately labelled cryo-vials and 
stored at − 80 °C until testing.
Total  CMV nucleic acids were extracted from 200 µL 
plasma using the QIAamp MinElute Virus Spin Kit (Qia-
gen, Hilden, Germany). Then, 60 µL of total viral nucleic 
acids including CMV-DNA were eluted and immediately 
stored at − 80 °C for subsequent testing. CMV-DNAemia 
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detection and quantification was performed by quantita-
tive PCR (qPCR) using the RealStar CMV PCR kit v1.0 
(Altona Diagnostics, Hamburg, Germany). CMV-DNA 
was quantified using the QuantStudio 3 Real-Time PCR 
System (Applied Biosystems, CA). The detection limit 
was 1 copy per mL.
For HIV, viral nucleic acids were extracted from 1 mL 
maternal baseline plasma and HIV-1-RNA quantified 
using an automated TaqMan Roche Amplicor 1.5 Moni-
tor Test (Cobas AmpliPrep/Cobas TaqMan, Roche Diag-
nostics, Branchburg NJ), according to the manufacturer’s 
instructions. The detection limit was 20 copies per mL.
Assessment of adverse birth outcomes
Adverse birth outcomes included preterm birth 
(< 37 weeks of gestation), low Apgar scores at 5 min (< 7) 
and low birth weight (LBW, < 2500 g), weighed within the 
first hour of life, before significant postnatal weight loss 
had occurred. Head circumference and birth lengths were 
also measured in centimetres. Z-score transformation of 
infant birth weight and birth length followed normal dis-
tribution of WHO reference data of 2006. Transforma-
tion was performed using the R package “zscorer”.
Early infant HIV diagnosis
Venous blood (EDTA) or heel prick blood spots were 
collected and preserved on 903 protein saver card 
(number 105311018) at delivery, 10  days and 6, 10, 14 
and 24  weeks. Every infant blood sample of each study 
visit was processed and stored as dried blood spots and 
plasma at − 20 and − 80 °C, respectively for further eval-
uation, including HIV and CMV assessments. Infants’ 
HIV infection was detected using a qualitative 1.5 Roche 
Amplicor HIV-1 proviral DNA PCR kit (Roche Diagnos-
tics Incorporation, Branchburg, New Jersey).
Data management and statistical analysis
Data were entered and managed using Research Elec-
tronic Data Capture (REDCap v 8.0, © 2020); http://
www.redca p.uzchs .ac.zw/redca p/. Quality assurance on 
the accuracy of data entry included independent double 
entries and verification in cases of discrepancies.
Parameters from groups of HIV-infected/-uninfected 
and/or CMV-DNA positive (viremic) and negative 
(aviremic) women were compared using the Kruskal 
Wallis test, Mann–Whitney U test, Chi-squared test and 
Fisher exact test where appropriate. For all serology posi-
tive test results, undetectable levels of HIV-1-RNA load 
or CMV-DNA were assigned the value zero. For multi-
variate linear and logistic regression analyses, the follow-
ing predictors: CMV-DNAemia of > 50 copies per mL, 
HIV-1-RNA load, years since HIV diagnosis, ongoing 
cART use duration and maternal age, all at the time of 
enrolment were tested.
For infant outcomes, all infants (including twins) were 
included, and for each infant the respective maternal 
parameters were used (resulting in usage of the same 
maternal parameters for both twins). For maternal out-
comes (e.g. prediction of maternal HIV-1-RNA load) the 
mothers with twin deliveries were counted once.
Automated parameter elimination for optimization of 
the Akaike information criterion using the “glmulti” R 
package was done. Due to limited statistical power, we 
did not consider interaction between predictors. All cal-
culations were performed in R Studio 1.2.5001.
Results
Study participants
From 527 pregnant women recruited between March 
2016 and August 2017, 280 (53%) were HIV-infected and 
247 (47%) were HIV-uninfected.
For the antenatal plasma CMV-DNA analysis, we 
selected all 11 HIV-infected mothers with subsequent 
HIV-MTCT as cases (HIV transmitters) and randomly 
selected 120 HIV-infected but non-transmitting mothers 
and their 123 infants (3 twin pregnancies) as controls, as 
well as 46 HIV-uninfected mothers and their 46 infants 
(no twin pregnancies). A total of twelve stillbirths were 
observed, of which 9 were HIV exposed but were not 
tested for in utero HIV infection, Fig. 1.
No relevant differences were observed between the 
randomly selected mothers included in the CMV-DNA 
analysis and the rest from the UZBCS population (Addi-
tional file 2: Tables 1, 2).
Baseline characteristics stratified by HIV status of all 
the pregnant women included in the CMV-DNA analy-
sis (N = 177) are presented in Table  1. HIV-infected 
pregnant women were significantly older (p = 0.031) but 
showed similar anthropometric measures and socio-
demographic characteristics with regards to family 
income, household size and number of infants < 5  years 
old living in the household. As expected, HIV-infected 
pregnant women with CMV viremia had lower haemo-
globin levels (p = 0.02), Additional file 2 : Table 3).
Of the 131 of HIV-infected pregnant women, regard-
less of the vertical transmission status, 28 (21%) had their 
first diagnosis of HIV done at enrolment into our study, 
and hence they were cART naïve. 103 were already on 
cART at enrolment, and of these, 27 (26%) were on cART 
for < 30  days, [median (1st quartile-3rd quartile); min–
max]; [11 [2–24]; 1–29] and 76 pregnant women were 
on cART for > 30 days, [799 (141–1677); 32–4327], with 
self-reported cART adherence rates of 100% and 87.5%, 
respectively. HIV-RNA load of ≥ 1000 copies/mL were 
observed in 54/129 (42%) of the pregnant women (2 cases 
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of missing data). As expected, cART use was strongly 
associated with lower HIV-RNA load, but no further 
trends were detected (Additional file 2: Table 4).
HIV exposed still born infants not tested for in utero 
infection were excluded from HIV-MTCT analysis, 
observed in 11 infants (4.0%). The timings of HIV infec-
tion of these infants were 1 (9%) and 3 (27%), in utero 
and intrapartum, born of the cART naïve mothers 
and < 30 days duration of cART use groups, respectively. 
The remaining infants 7 (64%) were infected through 
breastfeeding and were all born of mothers with > 30 days 
duration of cART usage. Of these 7 postpartum transmit-
ting mothers, 2 had HIV-1-RNA loads of < 20 copies/mL.
CMV viremic and CMV non‑viremic pregnant women
Plasma CMV-DNA was detected at comparable frequen-
cies in HIV-uninfected and -infected pregnant women 
(HIV-uninfected: 10/46, 21.7%; HIV-infected: 32/131, 
24.4%; p = 0.841), although a non-significant associa-
tion of higher CMV-DNA levels with HIV-infection was 
observed (Table 1).
In a multivariate analysis, neither HIV status nor 
maternal age nor socio-demographic parameters such 
as number of children under five years in the household 
were significantly associated with CMV-DNA load (Addi-
tional file  2: Table  5). CMV-DNA load of > 1000 copies/
mL were observed in 6 out of 177 women (3.4%), whilst 
higher load of > 10,000 copies/mL was detected in only 
one HIV-uninfected woman. CMV-DNA levels were sig-
nificantly higher in immunosuppressed pregnant women 
with CD4 < 200 cell per µL (p = 0.018, Mann–Whitney U 
test).
Association of CMV DNA levels with HIV vertical 
transmission
In our pilot study, 130 infants born of HIV-infected preg-
nant women were examined for HIV-MTCT (Fig. 1). 11 
with vertical HIV transmission events were included 
as cases. In comparison with the control sample of 119 
infants without MTCT, CMV-DNAemia was associ-
ated with HIV-MTCT, since MTCT was observed in 
6/32 (19%) CMV-DNA viremic mothers compared to 
only 5/98 (5.0%) of CMV-aviraemic mothers (p = 0.026, 
Fig. 2).
This association was confirmed in a multivariate analy-
sis. A non-significant association of higher HIV-MTCT 
with mothers having CMV viraemia of ≥ 50 copies/mL 
and MTCT independent of maternal plasma HIV-1-
RNA load was observed before parameter elimination 
(OR 3.62, CI 0.81–16.29, p = 0.085, Table  2). However, 
after parameter elimination, the association of CMV 
viremia ≥ 50 copies/mL at enrolment with HIV-MTCT 
Fig. 1 Flow chart of mothers’ subgroups. Flow chart illustrating mothers’ subgroups for different analyses. * Differences between numbers of 
mothers and numbers of infants are due to twin pregnancies
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was significant (OR 4.02, CI 1.09–15.30, p = 0.035, 
Table 2).
Association of CMV with plasma HIV‑1‑RNA load
Associations of different parameters with plasma HIV-
1-RNA load were examined in HIV-infected but non-
transmitting mothers. In a multivariate linear regression 
analysis, CMV-DNAemia of ≥ 50 copies/mL and also 
CMV-DNA load (copies/mL) as continuous variable were 
significantly associated with higher HIV-1-RNA load 
(both p = 0.002) while as expected cART usage correlated 
with lower HIV-1-RNA load (Table 3, Fig. 3, Additional 
file 1: Fig. 1). These parameters remained significant after 
automated parameter elimination.
Association of CMV levels with delivery before 37 weeks
We tested whether CMV levels were a predictor for 
preterm births before 37  weeks gestation in the sample 
of 123 infants born of HIV-infected but non-transmit-
ting mothers (120 mothers; 3 twin pregnancies) and 46 
infants born of 46 HIV-uninfected mothers. Multivari-
ate logistic regression analysis showed a non-significant 
association (p = 0.269) of more deliveries before 37 weeks 
of pregnancy among mothers with CMV-DNAemia ≥ 50 
copies/mL (Additional file 2: Table 6).
When we limited the multivariate analysis to infants 
born of HIV-infected but non-transmitting mothers, this 
trend showed a borderline statistical significance (OR 
2.71, CI 0.94–7.88, p = 0.063, Table  4). This association 
was robust to parameter elimination (OR 2.37, CI 0.88–
6.29, p = 0.083, Table 4). In the same analysis, time since 
Table 1 HIV-infected and uninfected study participants
Pregnant women characteristics, stratified by HIV status and CMV-DNAemia, 4 groups. Data are expressed as N (%) or median (IQR); min–max unless stated otherwise. 
For calculation of vertical transmissions only infants that survived the first 6 months of life were included; exclusions due to death are marked with one “†” for each 
deceased infant. P-values to compare groups were calculated using the Kruskal Wallis test, Mann–Whitney U test or Fisher’s exact test where appropriate. Missing 
data are indicated in the following manner: number of * = number of missing data points. Maternal age (years), Vertical transmission by 6 months of age both p 
values = 0.03, otherwise all the other p values are > 0.1
BMI: body mass index, CMV: cytomegalovirus, HIV: human immunodeficiency virus, WHO: world health organization, N/A: not applicable
Variables Median (1st quartile‑
3rd quartile); min–max
Stratifications; HIV status and CMV‑DNAemia; N = 177
Maternal HIV status HIV‑uninfected mothers, N = 46 HIV‑infected mothers including vertical 
transmitters, N = 131
CMV‑DNAemia CMV aviremic, N = 36 CMV viremic, N = 10 CMV aviremic, N = 99 CMV viremic, N = 32
CMV viremic (detectable) Yes N/A 10(21.7%) N/A 32(24.4%)
No 36 (78.3%) N/A 99(75.6%) N/A
CMV‑DNA (copies/mL) N/A 178 (126–344); 82–30,279 N/A 345 (207–500); 30–3169 
Maternal age (years) 24.4 (21.7–29.8); 18.1–41.7 26.3 (22.5–34.1); 17.6–40.1 29.5 (25.2–34.2); 18.4‑.43.7 28.3 (23.3–32.6); 18.3–41.7*
Mid upper arm circumfer‑
ence (cm)
28.5 [26–30]; 20–42 27 (25.3–28.8); 23–35.5 28 [26–30]; 21–39 27.3 [25–30]; 22–35
HIV‑RNA (copies per mL) N/A N/A 195 (20–10784.5); 
0–257539**
1665 (20–81, 150); 0–614706
CD4 count cells/µL N/A N/A 404.5 (277–517); 55–966*  341 (122–470); 26–1153
Pregnancy outcomes 
(N = 180 infants, includ‑
ing 3 sets of twins)
CMV aviremic mother, 
N = 36
CMV viremic mother, 
N = 10
CMV aviremic mother, 
N = 101
CMV viremic mother, N = 33
Delivery < 37 weeks gesta‑
tional age
Yes 7 (19.4%) 1 (10%) 22 (21.8%) 12 (36.4%)
No 29 (80.6%) 9 (90%) 79 (78.2%) 21 (63.6%)








Birth weight z score (WHO 
Growth Reference 2016)
− 0.6 (− 1.3‑(‑)0.0); 
− 3.8–1.1
− 0.7 (− 0.9‑(‑)0.7); 
− 1.7–1.1
− 0.9 (− 1.7‑(‑)0.2); 
− 5.5–1.5
− 1.2 (1.9‑(‑)0.1); − 6.8–0.5
Birth length (cm) 49(48–51); 42–58 51 (49.3–52); 47–56 49.(48–51*); 36–55*** 49 (48–50); 27–56 *
Birth length z score (WHO 
Growth Reference 2016)
− 0.1 (− 0.7–0.6); − 4.2–4.8 0.8 (− 0.0–1.5); − 1.5–3.7 − 0.1 (1.0–0.6); − 7.3–2.7 
***
− 0.5 (− 1.0–0.5); − 12.1–3.7 
*
Vertical transmission by 
6 months of age
Yes N/A N/A 5 (5.2%) †††† 6 (18.2%)*
No N/A N/A 92 (94.8%) †††† 27 (81.8%)
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the HIV diagnosis was a significant predictor for deliv-
ery before 37  weeks (OR 0.73, CI 0.55–0.91, p = 0.011, 
Table 4), independent of maternal age.
Among HIV-infected pregnant women, delivery 
before 37  weeks gestation was frequent (34/134, 25.4%) 
with lower rates observed among those with success-
ful cART with HIV-1-RNA load of < 20 copies per mL 
(7/39, 17.5%). We limited the logistic regression analy-
sis to HIV-infected but non-transmitting mothers under 
successful cART (≤ 20 copies/ mL). In this collective, no 
association of more frequent deliveries at < 37 weeks with 
CMV-DNAemia ≥ 50 copies/mL remained (p = 0.861, 
Additional file 2: Table 7).
Association of antenatal CMV DNA levels with infant birth 
weight
An association of lower birth weight of infants born 
from HIV-infected mothers and/or mothers with CMV-
DNAemia was noted but failed to reach statistical sig-
nificance (p = 0.450). Further, antenatal CMV-DNAemia 
was associated with lower birth length in some but not all 
analyses (Table 1, Additional file 2: Table 1).
Fig. 2 Association of HIV‑MTCT and maternal CMV‑DNA levels. 
Illustration depicting the relative shares of mothers with CMV‑DNA 
of > 50 copies/mL stratified for HIV‑MTCT status. P‑value was 
calculated using Fischer’s exact test
Table 2 Predictors of HIV-MTCT 
Logistic regression showing the association of different variables with MTCT in HIV-infected mothers with live infants. Results are presented as odds ratios; p-values 
are indicated as follows: *p < 0.1, **p < 0.05, ***p < 0.01. 128 infants were analysed (excluded: 2 due to missing data, 4 stillbirths)
CI: 95% confidence interval, CMV: cytomegalovirus, cART: combination anti-retroviral treatment, HIV: human immunodeficiency virus
Dependent variable: HIV transmission (yes/no)
Without variable elimination With variable elimination
Logistic regression results—odds ratios for vertical HIV transmission risk
Maternal CMV‑DNA of > 50 copies/mL (yes/no) 3.62 (CI 0.81–16.29) * 4.02 (CI 1.09–15.30) **
Maternal HIV‑RNA load (per 1000 copies/mL) 1.05 (CI 0.99–1.14)
Years with HIV diagnosis 1.09 (CI 0.93–1.26) 1.12 (CI 0.97–1.30) *
On cART (yes/no) 1.08 (CI 0.96–1.22)
Maternal age (years) 3.81 (CI 0.39–167.23)
Table 3 Predictors of maternal HIV-1-RNA load
Linear regression showing the association of different variables with maternal HIV-1-RNA load in HIV-infected but non-transmitting mothers. Results are presented as 
linear coefficients per 10.000 HIV copies/mL; p-values are indicated as follows: *p < 0.1, **p < 0.05, ***p < 0.01. 118 mothers were analysed (excluded: 2 due to missing 
data, 4 stillbirths and 11 MTCT cases)
CI: 95% confidence interval, CMV: cytomegalovirus, cART: combination anti-retroviral treatment, HIV: human immunodeficiency virus
Dependent variable: maternal HIV‑RNA load (10,000 copies/mL)
Without variable elimination With variable elimination
Linear regression results—linear coefficients for antenatal HIV-RNA load
Maternal CMV‑DNA > 50 copies/mL (yes/no) 4.15 (CI 1.57–6.74) *** 4.07 (CI 1.53–6.65) ***
Years with HIV diagnosis − 0.10 (CI − 0.47–0.27)
On cART (yes/no) − 3.32 (CI − 6.05‑(‑)0.60) ** − 3.58 (CI − 6.04‑(‑)1.11)***
Maternal age (years)  < 0.01 (CI − 0.19–0.19)
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Discussion
In this pilot study, we used data from UZBCS to test the 
association between antenatal plasma CMV-DNAemia 
and HIV-MTCT in a case–control design of 131 HIV-
infected pregnant women and their 134 HIV exposed 
infants (including 3 sets of twins). Our results indicate 
that pregnant women ≥ 20  weeks gestational age with 
CMV-DNAemia > 50 copies per mL had an odds ratio of 
approximately 4 for HIV-1 vertical transmission within 
the first 6 months of life.
In our pilot study, CMV-DNAemia did not differ 
regarding HIV status and cART use, suggesting CMV 
reactivation as a potential problem in pregnant women 
regardless of HIV status. These results contrast with 
previous findings where CMV reactivation occurred 
more frequently in HIV-infected but non-pregnant 
American women, even among those on cART [22]. 
Furthermore, no significant association between mater-
nal age and CMV-DNA load was apparent in our pilot 
study, most likely due to the much younger age of 
pregnant women of our cohort, in contrast to a Bra-
zilian study that observed higher CMV-DNA loads in 
relatively older  women [23]. Generally, differences may 
potentially be related to distinct environmental expo-
sures including presence of other co-infections in SSA 
compared to Western countries.
Antenatal plasma CMV-DNAemia of > 50 copies per 
mL was a significant predictor for HIV vertical trans-
mission (OR 4.02, CI 1.09–15.30, p = 0.035), which is 
in agreement with previous findings [24]. Similarly, in 
a clinical trial of South African and American cART 
naïve pregnant women, urinary CMV levels were sig-
nificant risk factors for CMV and HIV transmission to 
infants [25].
Thirty six (36) % of the HIV vertical transmission 
occurred early, either in utero or intrapartum among 
cART naïve or mothers on cART for < 30  days. Some 
previous studies showed much  higher rates of intrau-
terine HIV infection of about 70% (26, 27) versus 
just 9% observed in our study. The difference could be 
that these previous studies assessed HIV vertical trans-
mission in infants with an already confirmed CMV 
infection.
CMV has been shown to enhance placenta suscep-
tibility and replication of HIV-1, and may facilitate in 
utero HIV transmission [28]. In line with these find-
ings, the presence of CMV DNAemia in HIV-infected 
mothers might be the underlying reason behind our 
earlier observation of pregnant women who transmit-
ted HIV to their infants despite having low antenatal 
HIV-1-RNA-loads of < 20 copies/mL [29].
Fig. 3 HIV‑1‑RNA  loads stratified for CMV‑DNA. Bar plot of mothers’ 
HIV‑1‑RNA  loads stratified for maternal CMV‑DNA of > 50 copies/mL. 
Dashed lines indicate groups’ means
Table 4 Predictors for pre-term birth (< 37 weeks of pregnancy)
Logistic regression showing the association of different variables with preterm birth in HIV-infected but non-transmitting mothers. Results are presented as odds 
ratios; p-values are indicated as follows: *p < 0.1, **p < 0.05, ***p < 0.01. 121 participants were analysed (excluded: 2 due to missing data, 4 stillbirths and 11 MTCT 
cases)
CI: 95% confidence interval, CMV: cytomegalovirus, cART: combination anti-retroviral treatment, HIV: human immunodeficiency virus
Dependent variable: preterm birth (< 37 weeks)
Without variable elimination With variable elimination
Logistic regression results—odds ratios for preterm birth risk in HIV-infected women
Maternal CMV‑DNA of > 50 copies/mL (yes/no) 2.71 (CI 0.94–7.88) * 2.37 (CI 0.88–6.29) *
Maternal HIV‑RNA load (per 1000 copies/mL) 0.97 (CI 0.88–1.05)
Years with HIV diagnosis 0.73 (CI 0.54–0.92) ** 0.73 (CI 0.55–0.91) **
On cART (yes/no) 0.53 (CI 0.18–1.52)
Maternal age (years) 1.06 (CI 0.98–1.15)
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We also observed higher CMV-DNA levels in pregnant 
women with baseline absolute CD4 counts < 200 cells/µl, 
in line with other reports of CMV-DNA load as a marker 
for immunosuppression and elevated HIV-1-RNA load 
[30].
In a North American   study, the risk of infant hearing 
deficit increased with higher   antenatal plasma CMV-
DNA of ≥ 17,000 copies/mL [31]. However, there is still 
insufficient local/African data to define reliable viral load 
cut-offs to indicate disease severity or justify the need for 
CMV-specific antiviral treatment. Our data indicate that 
screening for CMV-DNA in pregnant women in SSA may 
provide useful information regarding infant prognosis.
Secondary analyses indicated higher rates of deliveries 
before 37 weeks gestation in HIV-infected CMV viremic 
women, although without statistical significance prob-
ably due to small sample size (p = 0.063 in the complete 
model, p = 0.083 after variable elimination, Table 4). This 
trend is not surprising since CMV infection has been 
shown to interfere with placental development, critical 
for the maintenance of a healthy pregnancy [32]. Pre-
term deliveries may occur due to CMV-induced maternal 
immune activation and systemic inflammatory caused by 
CMV reactivation in pregnancy [9].
We  observed an association with lower birth weight 
(> 2500  g) which also failed to reach statistical signifi-
cance, probably due to the limited power of our pilot 
study. In other studies, maternal CMV reactivation 
affected placental function, leading to intra-uterine 
growth retardation [32], which might lead to lower infant 
length for age and head circumference later in life.
Our pilot study has several strengths and limitations. 
Extensive clinical characterization of HIV-infected preg-
nant women with different duration of exposures to 
cART compared to their HIV-uninfected counterparts 
is a unique strength of our study. Further, all research 
participants reside in highly similar environmental con-
ditions in high-density areas of Harare resulting in an 
unusually homogenous study population. Limitations 
include the modest number of participants for which 
CMV-DNA levels were available and our pilot study 
may be underpowered for other potential adverse infant 
outcomes. Maternal HIV-RNA-load, the most signifi-
cant factor determining HIV vertical transmission was 
assessed once at enrolment and no additional meas-
urements of maternal HIV -1-RNA load are available 
until at exit.  cCMV infections and trends are yet to be 
assessed in all the infants born of 600 HIV-infected and 
600-uninfected pregnant women of the UZBCS, to inves-
tigate whether early HIV infection predisposes infants 
to CMV infection or the other way round. Further, our 
non-interventional study design does not allow us to dis-
tinguish whether CMV is an independent risk factor for 
HIV-1-MTCT or directly responsible for adverse out-
comes, so further mechanistic studies are needed in this 
regard.
Conclusion
Antenatal plasma CMV-DNA loads > 50 copies/mL may 
be an independent risk factor for HIV-1-MTCT, raising 
the possibility that controlling maternal CMV-DNAe-
mia levels might improve infant health outcomes. These 
findings should encourage fresh attempts to implement 
CMV diagnostics in clinical care for pregnant women 
and their infants in SSA. Further studies are warranted 
to determine whether anti-CMV treatment may improve 
pregnancy outcomes and infant health in low resource 
settings.
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P‑values to compare patient groups were calculated using the Mann‑
Whitney U test or Fisher’s exact test where appropriate. Missing data are 
indicated in the following manner: number of * = number of missing 
data points. Abbreviations: BMI: body mass index, CMV: cytomegalovirus, 
HIV: human immunodeficiency virus, WHO: world health organisation, 
N/A: not applicable. Table 2: HIV‑uninfected participants. Comparison of 
characteristics of HIV‑uninfected mothers between the study sample and 
the control sample. Data are expressed as n (%) or median (IQR); min‑max 
unless stated otherwise. P‑values to compare groups were calculated 
using Mann‑Whitney U test or Fisher’s exact test where appropriate. 
Missing data are indicated in the following manner: number of * = 
number of missing data points. Abbreviations: BMI: body mass index, CMV: 
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organisation, N/A: not applicable. Table 3: HIV‑infected and uninfected 
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CMV‑DNAemia (4). Data are expressed as n (%) or median (IQR); min‑max 
unless stated otherwise. P‑values to compare patient groups were calcu‑
lated using the Kruskal Wallis test, Mann‑Whitney U test or Fisher’s exact 
test where appropriate. Missing data are indicated in the following man‑
ner: number of * = number of missing data points. Abbreviations: BMI: 
body mass index, CMV: cytomegalovirus, HIV: human immunodeficiency 
virus, WHO: world health organisation, N/A: not applicable. Table 4: CMV 
viremic and aviremic participants. Sample characteristics stratified for HIV 
status, cART exposure and CMV status and analysis of differences in partic‑
ipant groups. Data are expressed as n (%) or median (IQR); min‑max unless 
stated otherwise. For calculation of vertical transmissions only infants 
that survived the first 6 weeks were included; exclusions due to death are 
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following manner: number of * = number of missing data points. Abbre‑
viations: BMI: body mass index, CMV: cytomegalovirus, cART: combination 
antiretroviral treatment, HIV: human immunodeficiency virus, WHO: world 
health organisation, N/A: not applicable. Table 5: Predictors of maternal 
CMV‑DNA load. Linear regression showing the association of different 
variables with maternal CMV‑DNA load in HIV‑infected non‑transmitting 
mothers after the removal of 0 outliers by the Tukey’s fences method (Q1 
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– 3×IQR and Q3 + 3×IQR). Results are presented as linear coefficients; 
p‑values are indicated as follows: *: p<0.1, **: p<0.05, ***: p<0.01. 121 
participants were analysed. Abbreviations: CI: 95% confidence interval, 
CMV: cytomegalovirus, cART: combination antiretroviral treatment, HIV: 
human immunodeficiency virus, IQR: interquartile range, Q: quartile. 
Table 6: Predictors for pre‑term birth (<37 weeks of pregnancy). Logistic 
regression showing the association of different variables with preterm 
birth in HIV‑infected but non‑transmitting mothers. Results are presented 
as odds ratios; p‑values are indicated as follows: *: p<0.1, **: p<0.05, ***: 
p<0.01. 169 participants were analysed. Abbreviations: CI: 95% confidence 
interval, CMV: cytomegalovirus. Table 7: Predictors for pre‑term birth 
(<37 weeks of pregnancy). Logistic regression showing the association of 
different variables with preterm birth in HIV‑infected but non‑transmitting 
mothers. Results are presented as odds ratios; p‑values are indicated as 
follows: *: p<0.1, **: p<0.05, ***: p<0.01. 36 participants were analysed. 
Abbreviations: CI: 95% confidence interval, CMV: cytomegalovirus, cART: 
combination antiretroviral treatment, HIV: human immunodeficiency virus.
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